

Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation

Yuan Zhu^{1,4,*}, Takayuki Harada¹, Li Liu⁴, Mark E. Lush¹, Frantz Guignard¹, Chikako Harada¹, Dennis K. Burns², M. Livia Bajenaru³, David H. Gutmann³ and Luis F. Parada¹

¹Center for Developmental Biology and Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, TX 75390-9133, USA

²Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9133, USA

³Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA

⁴Division of Molecular Medicine and Genetics, Departments of Internal Medicine and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

*Author for correspondence (e-mail: yuanzhu@umich.edu)

Accepted 12 October 2005

Development 132, 5577-5588

Published by The Company of Biologists 2005

doi:10.1242/dev.02162

Summary

The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene. Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS). Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits. In the present study, we have sought insight into the molecular and cellular basis of NF1-associated CNS pathologies. We show that mice genetically engineered to lack NF1 in CNS exhibit

a variety of defects in glial cells. Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves. As a consequence, all of the mutant optic nerves develop hyperplastic lesions, some of which progress to optic pathway gliomas. These data point to hyperproliferative glial progenitors as the source of the optic tumors and provide a genetic model for NF1-associated astrogliosis and optic glioma.

Key words: Neurofibromatosis type 1, Optic glioma, Glial progenitor, Astrocyte, Tumor suppressor gene, Mouse

Introduction

Astrocytic tumors or astrocytomas account for a vast majority of primary central nervous system (CNS) tumors (Holland, 2001; Kleihues and Cavenee, 2000; Maher et al., 2001; Zhu and Parada, 2002). According to the World Health Organization (WHO) grading system, astrocytomas can be classified into four histopathological grades. Grade II-IV astrocytomas are malignant neoplasms that diffusely infiltrate surrounding brain structures. Such astrocytic neoplasms may occur at any age, but are more common in adults than in children. By contrast, pilocytic astrocytomas, classified as Grade I neoplasms in the WHO grading scheme, are generally benign and tend to be better circumscribed (Holland, 2001; Kleihues and Cavenee, 2000; Maher et al., 2001; Zhu and Parada, 2002). Although pilocytic astrocytoma is the most common glioma in children, the molecular and genetic basis is largely unknown.

Individuals afflicted with a familial cancer syndrome, neurofibromatosis type 1 (NF1), are predisposed to the development of astrocytomas (Listernick et al., 1999). Approximately 15 to 20% of children with NF1 develop pilocytic astrocytomas predominantly within the optic pathway, hypothalamus and, occasionally, in the other brain areas (Listernick et al., 1999; Listernick et al., 1997). Like their

sporadic counterparts, most NF1-associated pilocytic astrocytomas are benign and can remain static for many years. However, despite histological benign features, a significant number of these tumors will endure and cause vision impairment and other neurological symptoms (Listernick et al., 1999). The *NF1* gene encodes the protein product, neurofibromin, which shares homology with members of the family of Ras GTPase activating proteins (GAPs) (Ballester et al., 1990; Viskochil, 1999; Xu et al., 1990). Like GAPs, neurofibromin attenuates the Ras-mediated signaling pathway by accelerating the conversion of activated Ras-GTP to inactive Ras-GDP. Consistent with the role of the *NF1* gene as a tumor suppressor gene, loss of heterozygosity at the NF1 locus and loss of neurofibromin expression have been observed in a variety of NF1-associated tumors, including astrocytomas (Gutmann et al., 2000; Kluwe et al., 2001). In one case report, loss of neurofibromin expression in an NF1-associated pilocytic astrocytoma correlated with the elevated Ras-GTP and activation of Ras downstream effectors such as mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI-3K) (Lau et al., 2000).

Functional activation of the Ras pathway through upregulation of receptor tyrosine kinases such as PDGF and

EGF receptors has been well documented in diffusely infiltrative malignant astrocytomas (Holland, 2001; Kleihues and Cavenee, 2000; Maher et al., 2001; Zhu and Parada, 2002). However, similar molecular alterations have not been observed in pilocytic astrocytomas (Gutmann et al., 2002; Li et al., 2001). It has been suggested that the *NF1* gene might be involved in regulating the proliferation of mature astrocytes (Bajenaru et al., 2002). Although neurofibromin is expressed below detection levels in normal astrocytes (Daston and Ratner, 1992; Daston et al., 1992; Huynh et al., 1994), it was reported that loss of *NF1* confers a growth advantage to neonatal astrocytes in vitro (Bajenaru et al., 2002). Conventional *NF1* knockout mice (*Nf1*^{-/-}) are embryonic lethal (Brannan et al., 1994; Jacks et al., 1994) and although heterozygous mice (*Nf1*^{+/-}) are cancer prone, they do not develop astrocytomas (Jacks et al., 1994). Conditional mutant mice lacking *NF1* specifically in neurons also fail to develop astrocytomas although increased number of non-neoplastic GFAP (glial fibrillary acidic protein) expressing reactive astrocytes was observed (Zhu et al., 2001). These results suggest that *NF1* can regulate the growth of astrocytes both intrinsically and also indirectly through neurons.

During embryonic development, multipotent neural stem/progenitor cells progressively lose developmental potential and become lineage-restricted neuronal progenitor cells or glial progenitor cells (Gage, 2000; Temple, 2001). Gliogenesis occurs after neurogenesis and extends into postnatal stages. In the setting of *NF1*, the greatest risk for development of optic glioma is the first 6 years of life (Listernick et al., 1999). This observation suggests that the *NF1* gene might play a role in regulating the proliferation of progenitor cells. Furthermore, recent reports demonstrate that pilocytic astrocytomas express molecular markers reminiscent of glial progenitor cells (Gutmann et al., 2002; Li et al., 2001).

To determine the role of *NF1* in the development of neural cell types and understand cellular and molecular basis of *NF1*-associated astrocytoma formation, we used a bacteriophage Cre/loxP system to target a *Nf1* mutation (Zhu et al., 2001) into multipotent neural stem/progenitor cells and their derivatives, including glia and neurons (Zhuo et al., 2001). We show that loss of *NF1* promotes the proliferation of glial progenitor cells resulting in increased numbers of GFAP-expressing astrocytes in both developing and adult brains. Furthermore, *NF1* also plays an indispensable role in the maintenance of the differentiation state of mature astrocytes. Finally, we describe a new mouse model for *NF1*-associated optic pathway glioma.

Materials and methods

Control and mutant mice

The control mice used in this study are the pool of phenotypically indistinguishable mice with genotypes *Nf1*^{flox/flox}, *Nf1*^{flox/+} and *Nf1*^{flox/+}; *hGFAP*-cre+. The mutant mice designated *Nf1*^{hGFAP} KO include both *Nf1*^{flox/-}; *hGFAP*-cre+ and *Nf1*^{flox/flox}; *hGFAP*-cre+, which have similar phenotypes. The genotyping procedures for the *Nf1*^{flox} allele, *Nf1*-null allele and Cre transgene have been described previously (Zhu et al., 2001).

Size and weight analysis of mice

Nf1^{hGFAP} KO and control littermates at the age of P0.5, P8 and 2 months were used to determine mass (g). Age-matched mutant and control mice were perfused with 4% paraformaldehyde (PFA). Brains

were dissected and post-fixed in 4% PFA overnight, and separated into forebrain and hindbrain for analysis. Statistical analysis was carried out using Student's *t*-test. *P*<0.05 was considered to be significant.

lacZ staining and double immunofluorescence

E10.5, E12.5 embryos or cryostat sections from postnatal or adult tissues were prepared and subjected to X-gal analysis as described previously (Zhu et al., 1998). Adjacent sections were subjected to double immunofluorescence with anti-*lacZ* (rabbit, 1:200, 5' and 3') and anti-NeuN (mouse, 1:200, Chemicon) or anti-*lacZ* and anti-GFAP (mouse, 1:100, Pharmingen).

BrdU assay

P8 mutant and control littermates were pulsed with BrdU for 2 hours, and adult mice (4–6 months) were pulsed with BrdU five times a day at 2-hour intervals. The dose of BrdU was 50 µg/g (gram, body mass). Mice were perfused with 4% PFA 2 hours after the last pulse. Brains were dissected and processed for either paraffin-embedded or cryostat sections. BrdU immunohistochemistry was performed as described previously (Zhu et al., 1998). The dilution of BrdU antibody was 1:50 (Becton Dickinson). The number of BrdU-positive cells was counted in one out of each ten serially prepared sections. Statistical analysis was carried out using Student's *t*-test. *P*<0.05 was considered to be significant.

Immunohistochemistry

After post-fixed in 4% PFA overnight, tissues were prepared for free-floating vibratome sections at 50 µm, cryostat sections at 14 µm or paraffin wax-embedded sections at 5 µm. Paraffin sections were deparaffinized and rehydrated. Sections were subjected to immunohistochemical analysis as described previously (Zhu et al., 2001). The visualization of primary antibodies was performed with either a horseradish peroxidase system (Vectastain ABC kit, Vector) or immunofluorescence by using Cy3-conjugated anti-rabbit/mouse and Cy2-conjugated anti-mouse/rabbit secondary antibodies at 1:200 dilution (Jackson Laboratories). The dilution of primary antibodies used in this study were: GFAP (rabbit, 1:2000, DAKO), nestin (mouse, 1:200, Chemicon), BLBP (rabbit, 1:1000, a gift from N. Heintz), PAX2 (rabbit, 1:1000, a gift from G. Dressler), P-erk (rabbit, 1:200, Cell Signaling), Cre (mouse, 1:1000, BABCO), Ki-67 (Rabbit, 1:1000, Novocastra Labs). Sections were examined under either light or fluorescence microscope (Olympus). The co-localization of two antigens was further confirmed by confocal microscopy (Zeiss).

Results

Generation of neural-specific *Nf1* knockout mice

Previous studies have shown that the Cre transgenic strain under the control of human GFAP promoter (*hGFAP*-cre) expresses Cre recombinase not only in mature astrocytes, but also in multipotent radial glial cells that exhibit neural stem/progenitor cell properties and can give rise to both glia and neurons during development (Malatesta et al., 2003; Malatesta et al., 2000; Noctor et al., 2001; Zhu et al., 2005; Zhuo et al., 2001). To target the *Nf1* mutation into neural stem/progenitor cells during development, we crossed the *hGFAP*-cre transgene to *Nf1*^{flox/-} and *Nf1*^{flox/flox} mice (Zhu et al., 2001). Resultant double transgenic *Nf1*^{flox/-}; *hGFAP*-cre+ and *Nf1*^{flox/flox}; *hGFAP*-cre+ mice were phenotypically indistinguishable, termed *Nf1*^{hGFAP} KO. The *Nf1*^{hGFAP} KO mice were born in appropriate Mendelian ratios although they exhibited growth retardation as early as P8 (see Fig. S1A in the supplementary material). In maturity, the weight differential between control littermates and *Nf1*^{hGFAP} KO mice

approached 50% (see Fig. S1A in the supplementary material). The mutant pups exhibited a series of abnormal neurological behaviors (data not shown) and failed to thrive. As shown in Fig. S1B (see supplementary material), the half-life for mutant mice was ~26 weeks and all mutants perished by 47 weeks of age.

In contrast to the diminished body weight, the *Nf1^{hGFAP} KO* mutant brain mass was slightly larger than that of control brains, although this did not reach statistical significance (0.54 ± 0.01 versus 0.52 ± 0.02 , $P=0.43$), except in the forebrain where the size of mutant tissues was significantly larger than that of controls (see Fig. S1C in the supplementary material, 1.08 ± 0.02 versus 0.94 ± 0.02 , $P=0.0003$).

Increased GFAP-positive astrocytes in adult *Nf1^{hGFAP} KO* mutant brains

To determine whether *Nf1^{hGFAP} KO* mutant brains have developmental or cellular defects, we performed histological analysis. Although the mutant cerebellum has conspicuous developmental defects that may contribute to the neurological abnormalities observed in mutant mice (see Fig. S1C in the supplementary material, data not shown), all other anatomical regions of *Nf1^{hGFAP} KO* brains appear relatively normal, including neuronal lamination in the cerebral cortex and hippocampus (see Fig. S2 in the supplementary material and data not shown). Immunohistochemical analysis with an antibody against GFAP revealed that *Nf1^{hGFAP} KO* mutant brains exhibited astrogliosis (see Fig. S2 in the supplementary material), a CNS pathology that is characterized by increased expression of GFAP coupled with hypertrophy of astrocytes, including enlarged somata and thickened processes (Ridet et

al., 1997). Staining of other astrocytic markers, including S100 β , further confirmed that *Nf1^{hGFAP} KO* mutant brains had increased numbers of astrocytes (data not shown). In contrast to our previous observation that neuronal loss of NF1 leads to astrogliosis restricted to the gray matter (Zhu et al., 2001), *Nf1^{hGFAP} KO* brains have extensive astrogliosis throughout both the gray and white matter, including the corpus callosum and anterior commissure (see Fig. S2I,J,M,N in the supplementary material). We next performed BrdU analysis to label proliferating cells and TUNEL analysis to detect apoptotic cells. Both analyses failed to detect significant differences between adult mutant and control brains (Fig. 1A and data not shown). Thus, the excess number of GFAP-positive astrocytes present in adult *Nf1^{hGFAP} KO* mutant gray and white matter probably results from early events that affect proliferation, apoptosis, differentiation or any combination of these factors.

Increased proliferating glial progenitor cells during development

To examine the status of glial progenitors in *Nf1^{hGFAP} KO* mutant brains, we selected postnatal day 8 (P8) for analysis. At P8, neurogenesis is largely complete but glial development and proliferation is still active (Bayer and Altman, 1991; Jacobson, 1991; Qian et al., 2000). P8 also coincides with the first detectable morphological differences between mutant and wild-type pups (see Fig. S1A in the supplementary material). The results of BrdU incorporation and immunohistochemical studies indicated that during development, mutant brains contain excess proliferating cells (Fig. 1B,C) that express a neural stem/progenitor cell marker, nestin (Fig. 2A,B), and an early glial progenitor cell marker, brain lipid binding protein




Fig. 1. Comparison of the number of BrdU-positive cells in adult and developing control and mutant brains. (A) The number of BrdU-positive cells in the cerebral cortex (Ctx), thalamus (Th) and cerebellum (Cb) of adult mutant brains ($n=6$) was not significantly different from those in adult control brains ($n=6$). The data plotted are mean \pm s.e.m. Cerebral cortex, $P=0.42$; thalamus, $P=0.46$; cerebellum, $P=0.57$. (B) The number of BrdU-positive cells in developing mutant brains ($n=5$) was significantly increased relative to those in controls ($n=3$). Cerebral cortex, $P=0.001$; thalamus, $P=0.007$. ** $P<0.01$. (C) Sections from the P8 control cerebral cortex (a,c) and thalamus (e,g), and the P8 mutant cortex (b,d) and thalamus (f,h) were stained with an anti-BrdU antibody. In contrast to the control P8 brains, which have low proliferation, the mutant brains contain significantly more BrdU-positive cells. Scale bars: 100 μ m.

(BLBP) (Fig. 2C,D) (Feng et al., 1994; Kurtz et al., 1994). Consistent with this, the majority of proliferating cells in both control (Fig. 2E,G) and mutant brains at P8 (Fig. 2F,H) do not express mature astrocyte markers, such as GFAP. We observed no difference in apoptosis between mutant and control brains that could contribute to the increased numbers of proliferating glial progenitors at this stage (data not shown).

To determine whether glial progenitor cells in P8 brains express the Cre transgene and hence are NF1 deficient, we performed immunohistochemical analysis. In both P8 control and mutant brains, most GFAP-positive astrocytes express the Cre transgene (Fig. 3; Fig. 4A), which is consistent with the previous observations in the adult brain (Malatesta et al., 2003; Zhu et al., 2005; Zhuo et al., 2001). However, not all of the Cre-positive cells expressed GFAP (Fig. 3A, parts a-d; 3B, parts a-d). Although these Cre-positive/GFAP-negative cells co-exist with Cre-positive/GFAP-positive astrocytes throughout the brain, they represent the major cell type in the

thalamus (Fig. 3A) and in the periphery of the cerebellar white matter (Fig. 3B), where we determined that most of these GFAP-negative cells express both Cre and BLBP (Fig. 3A, parts e,f; 3B, parts e,f). These data indicate that the Cre transgene is expressed in the BLBP-positive glial progenitor cells in both P8 control and mutant brains. Thus, we conclude that NF1 deficiency as a consequence of Cre-mediated recombination leads to increased numbers of proliferating glial progenitor cells in P8 brains.

***Nf1*^{-/-} glial progenitor cells differentiate**

We also determined an increased number of GFAP-positive astrocytes in P8 mutant brains (Fig. 2F,H; Fig. 3A, part b; Fig. 3B, part b; Fig. 4A, parts b,d) as compared with controls (Fig. 2E,G; Fig. 3A, part a; Fig. 3B, part a; Fig. 4A, parts a,c). To verify that the GFAP-expressing astrocytes in mutant brains are NF1 deficient, we used a Cre antibody to label *Nf1*^{-/-} cells. As shown in Fig. 4A, most of the GFAP-expressing cells in *Nf1*^{hGFAP} KO brains, including the cerebral cortex (Fig. 4A, part b) and the hippocampal dentate gyrus (DG) (Fig. 4A, parts d,f), co-express Cre and exhibit similar morphology to those astrocytes in control cortex (Fig. 4A, part a) and dentate gyrus (Fig. 4A, parts c,e). Furthermore, similar to normal counterparts (Fig. 4B, parts a,c), mutant astrocytes express GFAP but not nestin in most areas of P8 brains (Fig. 4B, parts b,d). A small number of cells expressing both GFAP and nestin were observed in both P8 control and mutant dentate gyrus (arrows in Fig. 4B, parts e,f) and the subventricular zone, which are probably neural stem/progenitor cells that persist into adulthood (Alvarez-Buylla et al., 2001). Thus, loss of NF1 promotes the proliferation of glial progenitor cells that retain the capacity to differentiate into GFAP-expressing astrocytes. We conclude that the tumor suppressor gene, NF1, is a negative regulator of the proliferation for glial progenitor cells but not for mature astrocytes.

A subset of *Nf1*^{-/-} astrocytes express nestin in the adult brain

In normal adult brains, nestin immunoreactivity is mainly restricted to the well-characterized sites of stem cell residence: the subgranular layer of the dentate gyrus (DG; Fig. 5A) and the subventricular




Fig. 2. Proliferating cells in P8 control and mutant brains express progenitor cell markers, not a mature astrocyte marker. Sections from P8 control and *Nf1*^{hGFAP} KO mutant brains were subjected to double-labeling immunofluorescence with anti-Ki67 (red) and anti-nestin (green) (A,B), with anti-BrdU (red) and anti-BLBP (green) (C,D), and with anti-BrdU (red) and anti-GFAP (green) (E,F). BrdU staining in the external granule cells in the P8 cerebella serves as an internal positive control for this study (E,F). (G,H) Higher magnification of sections in E,F, showing that only a small number of BrdU-positive cells in the mutant brain but not in the control brain expressed GFAP (arrows in H). (A-D) Sections from the thalamus. (E-F) Sections from the brainstem. IV, the fourth ventricle. Scale bars: 100 μ m.




Fig. 3. *hGFAP-cre* is expressed in glial progenitor cells during postnatal development. (A) Sections from the thalamus of P8 control (a,c,e) and mutant (CKO) brains (b,d,f) were subjected to double-labeling immunofluorescence with anti-Cre (red) and anti-GFAP (green) (a-d), and anti-Cre (red) and anti-BLBP (green) (e,f). (B) Sections from the cerebellar white matter of P8 control (a,c,e) and mutant brains (b,d,f) were subjected to double-labeling immunofluorescence with anti-Cre/anti-GFAP (a-d) and anti-Cre/anti-BLBP (e,f). The mutant cerebellar white matter has significantly more GFAP-positive cells than control (marked by broken lines in a-d). Most of the Cre-positive/GFAP-negative glial progenitor cells are distributed in the periphery of the cerebellar white matter (outside the broken lines). Arrows indicate glial progenitor cells expressing Cre and BLBP, but not GFAP. Genotypes: control mice, *Nf1^{fllox/+};hGFAP-cre+*; mutant mice, *Nf1^{fllox/-};hGFAP-cre+* or *Nf1^{fllox/flox};hGFAP-cre+*. Scale bars: 100 μ m.

zone of the lateral ventricle (LV; Fig. 5C) (Gage, 2000). In brains of a subset of aged *Nf1^{hGFAP}KO* mutant mice analyzed (8/14), nestin-positive cells were identified throughout the brain parenchyma, including the hippocampus (outside the subgranular layer, arrows in Fig. 5B) and cortex (Fig. 5D). All the nestin-positive cells had morphological features of mature astrocytes and co-expressed GFAP (Fig. 5B,D,H, inset), suggesting that these nestin/GFAP-positive cells represent abnormal astrocytes and that absence of NF1 results in abnormal co-expression of early and mature glial markers. In addition, consistent with NF1 inactivation, glial cells in *Nf1^{hGFAP}KO* mutant brains have elevated levels of activated MAPK (Fig. 5E,F). As the aberrant expression of nestin in *Nf1^{hGFAP}KO* mutant brains was only observed in a subset of aged (Fig. 5G,H), but not in P8 (Fig. 4B) or young adult (P30, data not shown) mutant mice, we suggest that NF1 may play a role in maintenance of the differentiated state of mature astrocytes in the adult brain.

We monitored a cohort of 45 *Nf1^{hGFAP}KO* mutant mice, 10 of which survived more than 8 months. Detailed histological analysis of mutant brains (cerebral cortex, hippocampus, thalamus, hypothalamus and cerebellum) revealed no evidence of tumor formation. Thus, despite the induced early progenitor hyperproliferation during development, loss of NF1 alone is not sufficient to cause astrocytoma formation in the brain. This

is consistent with the fact that while individuals with NF1 are reported to have a variety of brain abnormalities, including increased reactive astrogliosis (Nordlund et al., 1995), only a small percentage of these individuals develop astrocytomas in the brain (Listernick et al., 1999; Rubin and Gutmann, 2005).

Tumorigenic potential: a model for optic glioma

Approximately 15–20% of children with NF1 develop benign gliomas along the optic pathway with characteristics of pilocytic astrocytoma (Listernick et al., 1999). Using the *Rosa26-lacZ* reporter mouse strain (Soriano, 1999), we identified that *hGFAP-cre*-mediated recombination occurred in the optic nerve and the retina (Fig. 6A,B). The density of *lacZ*-positive cells appeared highest in the area of the optic nerve immediately adjacent to the retina (Fig. 6A–D). Double labeling with antibodies against *lacZ* and GFAP revealed that the majority of *lacZ*-positive cells in the optic nerve were GFAP-expressing astrocytes (Fig. 6C,D). Furthermore, *hGFAP-cre*-mediated recombination in the optic nerve was confirmed by PCR analysis (Fig. 6E) (Zhu et al., 2002; Zhu et al., 2005). We next examined the optic nerves from *Nf1^{hGFAP}KO* mutant mice along with control littermates. Of optic nerves from twenty nine mutant mice analyzed, 18 were significantly enlarged in diameter (Fig. 6F–H; Fig. 7A,B) and reminiscent of similarly prepared optic nerves from individuals




Fig. 4. *Nf1*^{-/-} glial progenitor cells undergo astrocytic differentiation. (A) Sections from P8 control (a,c,e) and *Nf1*^{hGFAP} *KO* mutant (b,d,f) brains were subjected to double-labeling immunofluorescence with anti-Cre (red) and anti-GFAP (green). (a,b) Sections from the control and mutant cerebral cortex (CC); (c-f) low (c,d) and high (e,f) magnification of sections from control and mutant hippocampal dentate gyrus (DG). Most of the GFAP-positive cells also express the Cre transgene. (B) Sections from the control and mutant P8 brains were subjected to double-labeling immunofluorescence with anti-nestin (red) and anti-GFAP (green). (a,b) Sections from the corpus callosum; (c,d) sections from the brainstem; (e,f) sections from the dentate gyrus. Most of the GFAP-positive astrocytes in both control and mutant P8 brains do not express nestin, except in the dentate gyrus (arrows in e,f), where a small number of cells express both GFAP and nestin. There are low levels of nestin expression in the endothelial cells. Genotypes: control mice, *Nf1*^{fllox/+}; *hGFAP*-cre+; mutant mice, *Nf1*^{fllox/-}; *hGFAP*-cre+ or *Nf1*^{fllox/fllox}; *hGFAP*-cre+. Scale bars: 100 μ m.

with NF1 with optic gliomas (Kleihues and Cavenee, 2000). Histological analysis revealed evidence of disorganization and increased cellularity throughout the optic nerves from all of the 29 mutant mice (Fig. 7C,D). The dysplastic nature of the cells in the mutant optic nerves is illustrated by double labeling with nestin and GFAP (Fig. 7E-H). We found that mature optic nerve astrocytes retain low levels of nestin expression (Frisen et al., 1995). Furthermore, consistent with the pattern of *hGFAP*-cre-mediated recombination in the optic pathway, the most pronounced changes were found in the area immediately adjacent to the retina (Fig. 7I,J), which contained dense clusters of randomly oriented glial nuclei. Detailed pathological analysis revealed that six out of 29 mutant mice (6/29) developed conspicuous neoplastic lesions (Fig. 8A-C). In contrast to normal nerves, which are comprised of well-organized astrocytes expressing both nestin and GFAP (Fig. 8D), neoplastic cells are completely disorganized and downregulate nestin expression (Fig. 8E,F). Although the optic nerve lesions observed in this tumor model lack some common features of pilocytic astrocytomas, such as Rosenthal fibers and granular bodies, these lesions display pathological features similar to human tumors, which include the location in the anterior optic nerve, coarse fibrillary appearance and nuclear

pleiomorphism with clustered atypical tumor nuclei (also see Fig. 9K,M).

BrdU analysis showed that mutant optic nerves contain five- to ten-fold increases in proliferating cells (Fig. 9A). In all cases, proliferating cells in both adult control (Fig. 9B,D) and mutant nerves (Fig. 9C,E) did not express GFAP, indicating that, as in the developing brain, loss of NF1 promotes the proliferation of progenitor cells in the optic nerve. By contrast, BrdU-positive cells in the optic nerve express nestin (arrows in Fig. 9F,G). These observations suggest that *Nf1*^{hGFAP} *KO* mutant optic nerves contain increased numbers of glial progenitor cells. When compared with adult control proximal (Fig. 9H,J) and distal (Fig. 9L) optic nerves that had few or no BLBP-expressing cells, adult mutant nerves contained numerous BLBP-positive cells that exhibited nuclear atypia indicative of neoplastic transformation (Fig. 9I, arrows in Fig. 9K,M). In addition, we also used an independent glial progenitor marker, Pax2 (Mi and Barres, 1999), to confirm that mutant optic nerves had increased numbers of glial progenitor cells (Fig. 9N,O).

We confirmed that the pathology observed in the optic nerves results from loss of NF1 by immunohistochemical analysis with a Cre antibody (data not shown). Consistently, mutant glial cells have high MAPK activity (Fig. 10A-D) with





Fig. 5. A subset of *Nf1*^{-/-} astrocytes in the adult brain express nestin. Sections from adult control (A) and mutant (B) dentate gyrus (DG), as well as control (C) and mutant (D) cerebral cortex were subjected to double-labeling fluorescence with anti-nestin (red) and anti-GFAP (green). LV, lateral ventricle. Reactive astrocytes expressing both GFAP and nestin were observed only in the mutant brain (arrows in B,D). Immunohistochemical analysis with anti-P-erk of the control (E) and mutant (F) dentate gyrus. A population of nestin-positive reactive astrocytes (arrows in H, see inset for high magnification) was identified only in a subset of aged mutant brains, but not in control or mutant mice at young age (G). Scale bars: 100 μ m.

a subset of mutant glial cells showing activated MAPK but lacking GFAP. These results suggest that both glial progenitor cells (Fig. 10F, arrowheads) and astrocytes (Fig. 10F, arrows) in mutant optic nerves had activated MAPK. These observations suggest that activation of Ras/MAPK pathway as a consequence of NF1 inactivation may underlie hyperplasia and glioma formation in the mutant optic nerve.

To examine whether NF1 heterozygosity in surrounding cells contributes to the development of optic glioma, we crossed *Nf1*^{flox/flox} mice into a different GFAP-cre* transgenic strain (Bajenaru et al., 2002) that targets Cre-mediated recombination only in astrocytes of the retina (see Fig. S3A,B in the supplementary material). When crossed to the Rosa26-lacZ reporter strain, the GFAP-cre* activity showed co-expression with astrocytic markers (GFAP), but not with neuronal markers in retina (NeuN; see Fig. S3E,F in the supplementary material). In some regions of the brain, GFAP-cre*-mediated recombination occurred in both glia and neurons (see Fig. S3C,D in the supplementary material) (Fraser et al., 2004). Detailed analysis of the optic nerve in these aged *Nf1*^{flox/flox};GFAP-cre*+ mutant mice (12 months old) revealed no evidence of hyperplasia compared with that observed for *Nf1*^{hGFAP} KO. These results support the notion that the

Fig. 6. Cre-mediated recombination leads to enlarged optic nerves. X-gal staining of the proximal optic nerve immediately adjacent to the retina (A) and distal optic nerve near the chiasm (asterisk) (B). Optic nerves were dissected from 2-month-old mice with the genotype of *hGFAP-cre*+/+; *Rosa26-lacZ*/+ (*n*=3). (C,D) Adjacent sections to A,B were subjected to double-labeling immunofluorescence with anti-lacZ (red) and anti-GFAP (green). Most of the lacZ-positive cells are GFAP-expressing astrocytes. (E) *hGFAP-cre*-mediated recombination in the optic nerve was revealed by PCR analysis. Upper panel: a PCR assay identifying the floxed NF1 allele ($\times 1$) and recombined floxed allele (Δ) indicated that a significant number of the floxed NF1 alleles in the optic nerve (ON), cerebral cortex (Ctx) and hippocampus (Hp) of the *Nf1*^{flox/flox}; *hGFAP-cre*+/+ mice transformed into the recombined alleles. Bottom panel: a PCR assay that identifies the wild type (+) and the floxed ($\times 1$) NF1 allele confirmed the genotype of the tissues analyzed. (F) A representative of control (left) and mutant (right) eyes with the optic nerves and chiasm (arrowheads). High-magnification of view of control (G) and mutant (H) optic nerves with chiasm (asterisk). The mutant nerve has a conspicuous enlargement (indicated by broken lines and arrowheads). Scale bars: 100 μ m in A-D; 1 mm in F-H.



heterozygous state of surrounding cells may contribute to NF1 nullizygous glial hyperplasia and neoplasia in the optic nerve (Bajenaru et al., 2003).




Fig. 7. *Nf1^{hGFAP} KO* optic nerves are hyperplastic. Sections from control (A,C) and mutant (B,D) distal optic nerves and chiasmata (asterisk) were stained with Hematoxylin and Eosin. Arrows in A,B indicate the enlarged area of the nerves shown in C,D, respectively. Adjacent sections from control (E,G) and mutant (F,H) optic nerves were stained with anti-nestin (red) and anti-GFAP (green). Mutant optic nerves are enlarged (B), hyperplastic (D) and disorganized (F,H). Sections from control (I) and mutant (J) proximal optic nerves were stained with Hematoxylin and Eosin. The most pronounced hypercellularity was observed in the proximal optic nerves (J). Scale bars: 100 μ m.

Discussion

Through analysis of neural-specific NF1 knockout mice, we demonstrate that the NF1 tumor suppressor gene has pivotal roles in the appropriate development of the CNS glial cell lineage and that sustained increased proliferation in glial progenitor cells may underlie tumor formation in the optic nerve.

NF1 and proliferation of glial progenitor cells

Consistent with the role of NF1 as a tumor suppressor gene, recent studies have demonstrated that loss of NF1 function confers a growth advantage to a variety of cell types in vitro, including neural stem/progenitor cells in the embryonic forebrain (Dasgupta and Gutmann, 2005), oligodendrocyte precursor cells from the embryonic spinal cord (Bennett et al., 2003), Schwann cells (Kim et al., 1997) and fibroblasts (Rosenbaum et al., 1995), etc. However, because of early embryonic lethality of NF1 homozygous mutants, insights into the function of NF1 during late developmental stages and adulthood remain limited (Bajenaru et al., 2003; Bajenaru et al., 2002; Zhu et al., 2002; Zhu et al., 2001). For example, despite the fact that several lines of evidence point to the *Nf1* gene as a negative regulator of astrocyte proliferation (Bajenaru et al., 2002), the in vivo role of the *Nf1* gene in mature astrocytes has not been fully addressed. Our studies indicate that NF1-deficient mature astrocytes in the adult brain do not show a significant increase in proliferation. Instead, we show significantly increased proliferation during postnatal CNS development. These proliferating cells express progenitor cell markers found in both multipotent neural stem/progenitor cells and glial progenitor cells (Anthony et al., 2004; Feng et al., 1994; Frisen et al., 1995; Kurtz et al., 1994; Lendahl et al., 1990). We conclude that these proliferative cells most probably represent glial progenitor cells, as neurogenesis is largely complete and gliogenesis persists in the P8 brain (Bayer and Altman, 1991; Jacobson, 1991; Qian et al., 2000). Thus, our studies demonstrate that the *Nf1* gene is a negative regulator of proliferation in glial progenitor cells and provide evidence that the NF1-associated pathology observed in the adult brain could result from developmental defects.

NF1 in differentiation of the astrocyte lineage

Increased numbers of NF1-deficient, GFAP-positive mature astrocytes were observed in both developing and adult *Nf1^{hGFAP} KO* mutant brains. Because *hGFAP-cre* is expressed in a majority of astrocyte precursors, radial glia in the embryonic brain (Malatesta et al., 2003) and glial progenitor cells in the postnatal brain (this study), it is reasonable to assume that the majority of mutant astrocytes arise from NF1 deficient progenitor cells. Thus, in vivo, NF1 is dispensable for astrocytic differentiation. As no increased proliferation or reduced apoptosis was observed in NF1-deficient mature astrocytes in both P8 and adult brains, the increased numbers of GFAP-positive astrocytes in adult mutant brains probably result from excess generation of glial progenitor cells, as observed during development. In brains of a subset of aged *Nf1^{hGFAP} KO* mutant mice, we identified an unusual population of cells that express both nestin and GFAP. These nestin/GFAP-positive cells morphologically resemble reactive astrocytes that are hypertrophic with thickened and increased processes (Ridet et al., 1997), which are observed in both




Fig. 8. *Nf1^{hGFAP} KO* mice develop optic pathway gliomas. Two independent optic gliomas (B,C) are shown with Hematoxylin and Eosin staining and compared with the control (A). Adjacent sections from control (D) and mutant nerves with gliomas (E,F) were stained with anti-nestin (red) and anti-GFAP (green). Unlike the well-organized normal astrocytes that express both nestin and GFAP in control (D), most of the cells in optic gliomas express only GFAP (E,F, arrowheads). Scale bars: 100 μ m.

human and mouse NF1-deficient brains (Gutmann et al., 1999; Nordlund et al., 1995; Rizvi et al., 1999; Zhu et al., 2001). As these nestin/GFAP-positive cells were not observed in the brains of developing (P8) or young adult (P30) mutant mice, these observations suggest that NF1 may be required for the maintenance of the astrocytic differentiation state or possibly preventing mature astrocytes from undergoing abnormal differentiation. Previously, we have reported that neuronal loss of NF1 results in activation of MAPK in neurons but not in astrocytes, leading to reactive astrogliosis in a non-cell autonomous fashion (Zhu et al., 2001). Despite exhibiting morphological similarities, the reactive astrocytes observed in neuronal-specific NF1 (*Nf1^{Synt} KO*) mutant brains, do not express nestin (Zhu et al., 2001). Therefore, the aberrant expression of this CNS progenitor cell marker (nestin) could result in part from intrinsic loss of NF1 within astrocytes or its progenitor cells. This is consistent with the observation that astrocytes in *Nf1^{hGFAP} KO* brains have elevated levels of activated MAPK, while reactive astrocytes in *Nf1^{Synt} KO* brains do not (Zhu et al., 2001).

NF1, a tumor suppressor gene in optic nerve glial progenitor cells

The present results and previous reports indicate that loss of NF1 alone is insufficient to induce astrocytoma in the brain (Bajenaru et al., 2003; Bajenaru et al., 2002; Zhu et al., 2005). By contrast, *hGFAP*-cre-mediated NF1 inactivation results in fully penetrant glial cell hyperplasia and ~20% incidence of gliomas in the optic nerves. One likely reason for this optic nerve-specific neoplasia is that increased proliferation in the mutant brain is limited to development, while mutant optic nerves have sustained increased proliferation into adulthood. Our data indicate that the proliferating cells in mutant optic

nerves express glial progenitor cell markers including nestin, BLBP and Pax2. These progenitor-like cells display nuclear atypia, a characteristic feature of neoplastic cells, and have increased levels of activated MAPK. Together, these observations suggest that NF1 deficiency regulates glial progenitor cell proliferation, which is likely to underlie optic glioma formation in this model.

A model for optic pathway glioma

Histologically, pilocytic astrocytomas may contain a surprisingly wide range of patterns (Kleihues and Cavenee, 2000). In addition to some of the more common features, including recognizable bipolar cytoplasmic processes, brightly eosinophilic Rosenthal fibers and hyaline granular bodies, pilocytic astrocytomas may also contain areas of substantial nuclear pleomorphism, oligodendroglioma-like regions, areas of infiltrative growth and cells similar to those of diffuse WHO grade II astrocytoma. In the case of lesions lacking Rosenthal fibers and hyaline granular bodies, the distinction between diffuse and pilocytic astrocytomas may be extremely difficult (Kleihues and Cavenee, 2000). Thus, within the accepted variability of pilocytic astrocytomas, the lesions found in the mutant mice are consistent with early stage optic pathway gliomas. This phenotype is further consistent with the fact that individuals with NF1 develop astrocytic neoplasms predominantly along the optic pathway (Listernick et al., 1999).

While this manuscript was in preparation, a mouse model for NF1-associated optic pathway glioma was published using the conditional NF1 flox mouse strain described here together with the GFAP-cre* transgene (see Fig. S3 in the supplementary material) (Bajenaru et al., 2003). The pathology described by Bajenaru et al. is less severe, reminiscent of that described as hyperplasia in this study (Fig. 7). In addition,




Fig. 9. *Nf1^{hGFAP} KO* hyperplastic nerves have increased proliferation and express glial progenitor cell markers. (A) The quantification of BrdU-positive cells in the adult control (CTR) and mutant (CKO) distal (DN) and proximal (PN) nerves. The data plotted are mean \pm s.e.m. (distal nerve, CTR, $n=4$, CKO, $n=5$, $**P<0.001$; proximal nerve, CTR, $n=3$, CKO, $n=6$, $**P<0.001$). Sections from control (B,D) and mutant (C,E) distal (B,C) and proximal (D,E) optic nerves were stained with anti-BrdU (red) and anti-GFAP (green). Sections from control (F) and mutant (G) nerves were stained with anti-Ki67 (red) and anti-nestin (green). Arrows in B and C indicate proliferating cells that do not express GFAP. Arrows in F and G indicate nestin-positive proliferating cells (inset in G provides higher magnification). Sections from control proximal (H,J), mutant proximal (I,K), control distal (L) and mutant distal (M) optic nerves were stained with anti-BLBP. Arrow in J indicates a BLBP-positive cells with normal nuclei in the normal nerve; arrows in K,M indicate BLBP-positive cells with atypical nuclei in the mutant nerve. Sections from control (N) and mutant (O) optic nerves were stained with anti-Pax2. Scale bars: 100 μ m.

Bajenaru et al.'s study describes hyperplastic optic nerves only in the *Nf1^{flox/-}* genetic configuration and not in the *Nf1^{flox/flox}* configuration. Our *Nf1^{hGFAP} KO* mice exhibit fully penetrant hyperplasia in either the *flox/-* or the *flox/flox* configurations and, additionally, 20% incidence of optic pathway gliomas. Possible explanations for the discrepancy between these two studies include the timing of Cre transgene activation (E10.5 for *hGFAP-cre* versus E14.5 for *GFAP-cre**), contributions of NF1 deficient neighboring cells in the tumor micro-environment and differences in genetic background. In line with this study, it is tempting to speculate that the timing of NF1 inactivation in the glial cell lineage during optic nerve development may account in part for the heterogeneous nature of the NF1-associated optic gliomas (Listernick et al., 1999; Rubin and Gutmann, 2005). Thus, our model may mimic a subset of individuals with NF1 who have severe tumor phenotypes as a consequence of loss of NF1 in a progenitor

cell population, while the mouse strain developed by Bajenaru et al. may model less aggressive lesions owing to NF1 inactivation in more differentiated cells.

In this study, we compared Cre-mediated recombination in both *GFAP-cre* strains and found that the *GFAP-cre** transgene is active only in the retinal surface layer where astrocytes are located (see Fig. S3 in the supplementary material). By contrast, the *hGFAP-cre* activity is also observed in the inner retinal layer (Fig. 6A). Interestingly, this layer contains another retina-specific glia, called Müller cells. This cell type can produce and secrete various kinds of trophic factors and cytokines, which may regulate glia-glia and glia-neuron network under pathological conditions (Harada et al., 2002; Harada et al., 2000). It is therefore possible that in the context of NF1 loss, an enhanced paracrine interaction occurs between Müller cells and glial progenitor cells in the optic nerve. This would account for the robust appearance of tumors with our




Fig. 10. Glial cells in mutant optic nerves have elevated levels of activated MAPK. Sections of the proximal optic nerves from control mice (A,C) and mutant mice (B,D) were stained with anti-P-erk. The arrow in D indicates the tumor cells with activated MAPK. Sections from control (E) and mutant (F) optic nerves were subjected to triple labeling with anti-P-erk (red), anti-GFAP (green) and DAPI (blue). DAPI was used to label the nuclei. In contrast to the control nerves where little or no cells had activated MAPK (E), mutant nerves contained numerous P-erk positive cells, some of which co-expressed GFAP (F, arrows) and some of which failed to express GFAP (F, arrowheads). Scale bars: 100 μ m.

Nf1^{hGFAP} KO model that has NF1-null surrounding cells (e.g. Müller glia) compared with a partial hyperplastic response in the *Nf1^{lox/-};GFAP⁺-cre+* transgene where neighboring cells are heterozygous for NF1.

We thank P. Houston, A. DeShaw, S. McKinnon, W. Song and A. Wang for technical assistance; members of the Parada and Zhu laboratories for support; Dr N. Heintz for BLBP antibody; Dr G. Dressler for Pax2 antibody; and Dr S. Weiss for critically reading the manuscript. This work is supported by grants from the National Institute of Neurological Disorders and Stroke, the American Cancer Society and Department of Defense (L.F.P.); from the National Institutes of Health and DOD to D.H.G.; and by a NIH postdoctoral award to M.L.B. Y.Z. acknowledges support from National Neurofibromatosis Foundation (Young Investigator Award), the Biological Sciences Scholars Program and the Comprehensive Cancer Center of the University of Michigan Medical School.

Supplementary material

Supplementary material for this article is available at <http://dev.biologists.org/cgi/content/full/132/24/5577/DC1>

References

- Alvarez-Buylla, A., Garcia-Verdugo, J. M. and Tramontin, A. D. (2001). A unified hypothesis on the lineage of neural stem cells. *Nat. Rev. Neurosci.* **2**, 287-293.
- Anthony, T. E., Klein, C., Fishell, G. and Heintz, N. (2004). Radial glia serve as neuronal progenitors in all regions of the central nervous system. *Neuron* **41**, 881-890.
- Bajenaru, M. L., Zhu, Y., Hedrick, N. M., Donahoe, J., Parada, L. F. and Gutmann, D. H. (2002). Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. *Mol. Cell. Biol.* **22**, 5100-5113.
- Bajenaru, M. L., Hernandez, M. R., Perry, A., Zhu, Y., Parada, L. F., Garbow, J. R. and Gutmann, D. H. (2003). Optic nerve glioma in mice requires astrocyte *Nf1* gene inactivation and *Nf1* brain heterozygosity. *Cancer Res.* **63**, 8573-8577.
- Ballester, R., Marchuk, D., Boguski, M., Saulino, A., Letcher, R., Wigler, M. and Collins, F. (1990). The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. *Cell* **63**, 851-859.
- Bayer, S. A. and Altman, J. (1991). *Neocortical Development*. New York: Raven Press.
- Bennett, M. R., Rizvi, T. A., Karyala, S., McKinnon, R. D. and Ratner, N. (2003). Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. *J. Neurosci.* **23**, 7207-7217.
- Brannan, C. I., Perkins, A. S., Vogel, K. S., Ratner, N., Nordlund, M. L., Reid, S. W., Buchberg, A. M., Jenkins, N. A., Parada, L. F. and Copeland, N. G. (1994). Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. *Genes Dev.* **8**, 1019-1029.
- Dasgupta, B. and Gutmann, D. H. (2005). Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. *J. Neurosci.* **25**, 5584-5594.
- Daston, M. M. and Ratner, N. (1992). Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. *Dev. Dyn.* **195**, 216-226.
- Daston, M. M., Scrabble, H., Nordlund, M., Sturbaum, A. K., Nissen, L. M. and Ratner, N. (1992). The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. *Neuron* **8**, 415-428.
- Feng, L., Hatten, M. E. and Heintz, N. (1994). Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. *Neuron* **12**, 895-908.
- Fraser, M. M., Zhu, X., Kwon, C. H., Uhlmann, E. J., Gutmann, D. H. and Baker, S. J. (2004). Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. *Cancer Res.* **64**, 7773-7779.
- Frisen, J., Johansson, C. B., Torok, C., Risling, M. and Lendahl, U. (1995). Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. *J. Cell Biol.* **131**, 453-464.
- Gage, F. H. (2000). Mammalian neural stem cells. *Science* **287**, 1433-1438.
- Gutmann, D. H., Loehr, A., Zhang, Y., Kim, J., Henkemeyer, M. and Cashen, A. (1999). Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. *Oncogene* **18**, 4450-4459.
- Gutmann, D. H., Donahoe, J., Brown, T., James, C. D. and Perry, A. (2000). Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. *Neuropathol. Appl. Neurobiol.* **26**, 361-367.
- Gutmann, D. H., Hedrick, N. M., Li, J., Nagarajan, R., Perry, A. and Watson, M. A. (2002). Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. *Cancer Res.* **62**, 2085-2091.
- Harada, T., Harada, C., Nakayama, N., Okuyama, S., Yoshida, K., Kohsaka, S., Matsuda, H. and Wada, K. (2000). Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration. *Neuron* **26**, 533-541.
- Harada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L. F. and Wada, K. (2002). Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. *J. Neurosci.* **22**, 9228-9236.
- Holland, E. C. (2001). Gliomagenesis: genetic alterations and mouse models. *Nat. Rev. Genet.* **2**, 120-129.
- Huynh, D. P., Nechiporuk, T. and Pulst, S. M. (1994). Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development. *Dev. Biol.* **161**, 538-551.
- Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S.,

- Bronson, R. T. and Weinberg, R. A. (1994). Tumor spectrum analysis in p53-mutant mice. *Curr. Biol.* **4**, 1-7.
- Jacobson, M. (1991). *Developmental Neurobiology*. New York: Plenum Press.
- Kim, H. A., Ling, B. and Ratner, N. (1997). NF1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. *Mol. Cell. Biol.* **17**, 862-872.
- Kleihues, P. and Cavenee, W. K. (2000). *Pathology and Genetics of Tumors of the Nervous System*. Lyon, France: International Agency for Research on Cancer Press.
- Kluwe, L., Hagel, C., Tatagiba, M., Thomas, S., Stavrou, D., Ostertag, H., von Deimling, A. and Mautner, V. F. (2001). Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. *J. Neuropathol. Exp. Neurol.* **60**, 917-920.
- Kurtz, A., Zimmer, A., Schnutgen, F., Bruning, G., Spener, F. and Muller, T. (1994). The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. *Development* **120**, 2637-2649.
- Lau, N., Feldkamp, M. M., Roncari, L., Loehr, A. H., Shannon, P., Gutmann, D. H. and Guha, A. (2000). Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. *J. Neuropathol. Exp. Neurol.* **59**, 759-767.
- Lendahl, U., Zimmerman, L. B. and McKay, R. D. (1990). CNS stem cells express a new class of intermediate filament protein. *Cell* **60**, 585-595.
- Li, J., Perry, A., James, C. D. and Gutmann, D. H. (2001). Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. *Neurology* **56**, 885-890.
- Listernick, R., Louis, D. N., Packer, R. J. and Gutmann, D. H. (1997). Optic pathway gliomas in children with neurofibromatosis 1, consensus statement from the NF1 Optic Pathway Glioma Task Force. *Annu. Neurol.* **41**, 143-149.
- Listernick, R., Charrow, J. and Gutmann, D. H. (1999). Intracranial gliomas in neurofibromatosis type 1. *Am. J. Med. Genet.* **89**, 38-44.
- Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K. and DePinho, R. A. (2001). Malignant glioma: genetics and biology of a grave matter. *Genes Dev.* **15**, 1311-1333.
- Malatesta, P., Hartfuss, E. and Gotz, M. (2000). Isolation of radial glial cells by fluorescent-activated cell sorting reveals a neuronal lineage. *Development* **127**, 5253-5263.
- Malatesta, P., Hack, M. A., Hartfuss, E., Kettenmann, H., Klinkert, W., Kirchhoff, F. and Gotz, M. (2003). Neuronal or glial progeny: regional differences in radial glia fate. *Neuron* **37**, 751-764.
- Mi, H. and Barres, B. A. (1999). Purification and characterization of astrocyte precursor cells in the developing rat optic nerve. *J. Neurosci.* **19**, 1049-1061.
- Noctor, S. C., Flint, A. C., Weissman, T. A., Dammerman, R. S. and Kriegstein, A. R. (2001). Neurons derived from radial glial cells establish radial units in neocortex. *Nature* **409**, 714-720.
- Nordlund, M. L., Rizvi, T. A., Brannan, C. I. and Ratner, N. (1995). Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. *J. Neuropathol. Exp. Neurol.* **54**, 588-600.
- Qian, X., Shen, Q., Goderie, S. K., He, W., Capela, A., Davis, A. A. and Temple, S. (2000). Timing of CNS cell generation: a programmed sequence of neuron and glial cell production from isolated murine cortical stem cells. *Neuron* **28**, 69-80.
- Ridet, J. L., Malhotra, S. K., Privat, A. and Gage, F. H. (1997). Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci.* **20**, 570-577.
- Rizvi, T. A., Akunuru, S., de Courten-Myers, G., Switzer, R. C., 3rd, Nordlund, M. L. and Ratner, N. (1999). Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (NF1) tumor suppressor. *Brain Res.* **816**, 111-123.
- Rosenbaum, T., Boissy, Y. L., Kombrinck, K., Brannan, C. I., Jenkins, N. A., Copeland, N. G. and Ratner, N. (1995). Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. *Development* **121**, 3583-3592.
- Rubin, J. B. and Gutmann, D. H. (2005). Neurofibromatosis type 1 – a model for nervous system tumour formation? *Nat. Rev. Cancer* **5**, 557-564.
- Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **21**, 70-71.
- Temple, S. (2001). The development of neural stem cells. *Nature* **414**, 112-117.
- Viskochil, D. H. (1999). The structure and function of the NF1 gene: molecular pathology. In *Neurofibromatosis: Phenotype, Natural History, and Pathogenesis* (ed. J. M. Friedman, D. H. Gutmann, M. MacCollin and V. M. Riccardi), pp. 119-141. Baltimore: Johns Hopkins Press.
- Xu, G. F., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., White, R., Weiss, R. and Tamanai, F. (1990). The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of *S. cerevisiae*. *Cell* **63**, 835-841.
- Zhu, Y. and Parada, L. F. (2002). The molecular and genetic basis of neurological tumours. *Nat. Rev. Cancer* **2**, 616-626.
- Zhu, Y., Richardson, J. A., Parada, L. F. and Graff, J. M. (1998). Smad3 mutant mice develop metastatic colorectal cancer. *Cell* **94**, 703-714.
- Zhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., Marth, J. D. and Parada, L. F. (2001). Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. *Genes Dev.* **15**, 859-876.
- Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K. and Parada, L. F. (2002). Neurofibromas in NF1: Schwann cell origin and role of tumor environment. *Science* **296**, 920-922.
- Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A. and Parada, L. F. (2005). Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. *Cancer Cell* **8**, 119-130.
- Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K. and Messing, A. (2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. *Genesis* **31**, 85-94.